Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.
Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.
The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.
Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.
Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.
Zoetis Inc. (ZTS) reported Q4 2020 revenue of $1.8 billion, up 8% YoY, with net income of $359 million ($0.75/share). Adjusted net income was $438 million, relatively unchanged. Full-year revenue reached $6.7 billion, a 7% increase, with net income of $1.6 billion ($3.42/share). The company anticipates 2021 revenue growth of 9% to 11%, driven by strong performance in petcare and international markets. Key product approvals include Librela and Solensia for pain management in pets. Overall, Zoetis demonstrated resilience amidst COVID-19 challenges.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Feb. 16, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. CEO Kristin Peck and CFO Glenn David will present the information and answer questions from analysts. A live webcast will be accessible on the Zoetis investor website, and a replay will be available following the call. The company is a leader in animal health, offering medicines, vaccines, and diagnostics in over 100 countries, generating $6.3 billion in revenue in 2019.
Zoetis (NYSE:ZTS) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. CEO Kristin Peck is scheduled to present at 10:00 a.m. ET and answer analysts' questions. Investors can access a live audio webcast of the presentation via investor.zoetis.com. A replay will be available post-event. Zoetis is a leader in animal health, with over 65 years of experience, offering medicines, vaccines, and diagnostics in over 100 countries, generating $6.3 billion in revenue in 2019.
Zoetis Inc (NYSE:ZTS) has announced a 25% increase in its quarterly dividend, raising it to $0.25 per share for the first quarter of 2021. This increase reflects the company's strength and resilience in the animal health sector. The dividend will be paid on March 1, 2021, to shareholders on record as of January 20, 2021. Executive Vice President and CFO Glenn David noted the company's confidence in generating cash for future investments and their commitment to returning excess capital to shareholders.
Zoetis Inc (NYSE:ZTS) has appointed Antoinette Leatherberry to its Board of Directors, expanding the Board from 12 to 13 members. Leatherberry, a former Deloitte executive with 30 years of experience, will contribute to the Audit and Corporate Governance Committees. Her expertise in tech-enabled strategies aligns with Zoetis' goal of enhancing digital transformation in the animal health sector. Leatherberry has a strong track record in promoting diversity and holds significant educational qualifications, including a Mechanical Engineering degree and an MBA.
Zoetis Inc. (NYSE:ZTS) will participate in the Credit Suisse 2020 Virtual Healthcare Conference on November 10, 2020. Glenn David, Executive Vice President and CFO, will represent the company, presenting at 11:00 a.m. ET. Investors can access a live audio webcast of the presentation via Zoetis' investor relations site. A replay will also be available post-event. Zoetis is a leading animal health company with over 65 years of experience, generating $6.3 billion in revenue in 2019 and serving clients in over 100 countries.
Zoetis Inc (NYSE:ZTS) has announced a fourth-quarter dividend of $0.20 per share, set to be paid on December 1, 2020. The dividend will benefit stockholders of record as of October 21, 2020. With a strong market position in animal health, Zoetis generated $6.3 billion in revenue in 2019, underscoring its operational strength across 100 countries. This dividend declaration reflects the company's commitment to returning value to shareholders while maintaining a solid financial framework.
FAQ
What is the current stock price of ZOETIS (ZTS)?
What is the market cap of ZOETIS (ZTS)?
What does Zoetis Inc. specialize in?
Is Zoetis Inc. still part of Pfizer?
What percentage of Zoetis' revenue comes from companion animals?
Which segment contributes more to Zoetis' U.S. business?
How does Zoetis' international business differ from its U.S. business?
What recent achievements has Zoetis Inc. accomplished?
What are Zoetis' current projects?
What is Zoetis' market position in the industry?
Does Zoetis have any strategic partnerships?
Where can I find the latest updates on Zoetis Inc.?
